Rentokil Initial heads into its July 30 results with options traders leaning noticeably to the call side — an unusual tilt for a stock that has lost more than 6% in a week.
The most striking positioning signal is how far the put/call ratio has shifted toward calls. At 0.19, the PCR is running well below its 20-day average of 0.26 — nearly a standard deviation to the bullish side — and has compressed steadily since late June, when it was above 0.70. That drop happened even as the stock fell from roughly $30 to $28.37, down 6.6% on the week and almost 3% on Friday alone. Options traders are paying for upside exposure into a print where the price action has been squarely against them.
The lending market offers little ammunition for the bear side. Borrow availability is generous — around 380% of short interest — meaning there are nearly four shares available to borrow for every one already lent out. That compares to a 52-week low availability of 67.5%, a level never approached recently. Cost to borrow has also eased back to 0.77%, down from peaks above 1.5% earlier in July. Short interest itself ticked up about 5% on the week to roughly 2.52 million shares, but in the context of the broader lending pool that remains relaxed, short sellers face no meaningful squeeze pressure. The overall short score of 39 places RTO in a relatively benign position for bears.
The bull and bear cases for the July 30 print crystallise around one question: whether Rentokil's margin recovery story has legs. Bulls can point to the stock trading at 18x earnings — a multiple that has compressed meaningfully over the past month — and an EV/EBITDA of 47x that, while elevated, has been drifting lower for weeks. The analyst recommendation differential factor ranks in the 95th percentile, suggesting the Street's consensus direction is unusually bullish relative to peers. Bears counter with persistent integration costs from the Terminix acquisition and a quality picture that has deteriorated in recent months — the EV/EBIT factor score is in just the 13th percentile, a sign that earnings power relative to enterprise value remains a concern. The most recent earnings event in May produced a 2.3% decline on the day and a 5.9% drop over the following week, a pattern bears will flag as precedent. The March 2026 announcement, however, triggered a 10.8% single-day gain and a 13.4% five-day surge — so the stock has shown it can move sharply in either direction on results.
Notable institutional positioning adds a further wrinkle: Trian Fund Management trimmed roughly 23.5 million shares in the most recent reported period, cutting its stake meaningfully, while Invesco added 15.3 million shares and Independent Franchise Partners added 6.7 million. That divergence — an activist-linked seller against value-oriented buyers — reflects exactly the debate the print will be asked to resolve: whether Rentokil's operational improvement is accelerating fast enough to justify patience, or whether the integration timeline continues to disappoint.
The earnings release is therefore less about pest control volumes and more about whether management can demonstrate that North American margin recovery is on a credible trajectory — the single metric that will determine which side of that institutional divide proves right.
See the live data behind this article on ORTEX.
Open RTO on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
